Advertisement

Topics

BioMolecular Therapeutics Company Profile

00:27 EDT 25th June 2018 | BioPortfolio

BMT elucidates modulation of host defense mechanisms responsible for inflammatory and autoimmune diseases. The major disease areas in which BMT is conducting research are atherosclerosis, rheumatoid arthritis and certain forms of allergies. With a staff of more than 50 researchers and initial € 12 million of corporate and public funding, BMT generates break-through innovations which can be turned into marketable intellectual property rights. BMT provides attractive new technologies which are ready for industrial applications and which have substantial spin-off potential.
As a joint venture between the industrial partners Baxter, Technoclone and Polymun and academic partners from the Medical University Vienna and the University of Natural Resources and Applied Life Sciences, Vienna, BMT not only receives substantial funding (in-kind and cash) from pharmaceutical industry, but also contributes from the intellectual power of outstanding scientists from renowned academic institutes.

Location

Brunner Strasse 59,
Vienna
Vienna
A-1230
Austria

Contact

Phone: 43.1.867.3691
Fax: 43.1.867.3694
Email: office@bmt-research.at


News Articles [801 Associated News Articles listed on BioPortfolio]

Scientists Remove 'Biomolecular Brakes' on Plant Oil Production

Researchers from the U.S. Department of Energy's Brookhaven National Laboratory revealed the biomolecules that can put brakes on oil production of plants. When these biomolecular brakes are disabled, ...

NIH Common Fund Announces New Funding for Human Biomolecular Atlas Program (HuBMAP)

The National Institutes of Health Common Fund has recently announced a new funding opportunity from the Human Biomolecular Atlas Program (HuBMAP). HuBMAP aims to accelerate the development of the next...

What You Need to Know About Indalo Therapeutics

Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics.

Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, ...

www.wallstequities.com/registration Adaptimmune Therapeutics Shares in Abingdon, the UK headquartered Adaptimmune Therapeutics PLC rose slightly by 0.41%, ending Wednesday's trading session at $12...

Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions

About Proteostasis Therapeutics, Inc. Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (CF) and other di...

New computational strategy designed for more personalized cancer treatment

(Johns Hopkins University) Mathematicians and cancer scientists have found a way to simplify complex biomolecular data about tumors, in principle making it easier to prescribe the appropriate treatmen...

Anika Therapeutics (ANIK) versus Onconova Therapeutics (ONTX) Financial Survey

Anika Therapeutics and Onconova Therapeutics are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earn...

What You Need to Know About DMD Therapeutics

DMD Therapeutics is based in Seattle, although at present it is a virtual company, and, as its name suggests, is focused on developing therapeutics for DMD.

PubMed Articles [560 Associated PubMed Articles listed on BioPortfolio]

Thermophoresis for characterizing biomolecular interaction.

The study of biomolecular interactions is crucial to get more insight into the biological system. The interactions of protein-protein, protein-nucleic acids, protein-sugars, nucleic acid-nucleic acids...

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Clinical Trials [155 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1258 Associated Companies listed on BioPortfolio]

Centre for Molecular and Biomolecular Informatics

Welcome at the CMBI, which is short for Centre for Molecular and Biomolecular Informatics. The centre performs research and education, and provides services in bioinformatics and cheminformatics.

Association of Biomolecular Resource Facilities

The Association of Biomolecular Resource Facilities is an international society dedicated to advancing core and research biotechnology laboratories through research, communication, and education.

BioMolecular Therapeutics, Inc.

An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technolo...

Affigen

Affigen (www.affigen.com) develops tumor-identifying therapeutics that target cell lineage-specific tumor proteins in certain incurable cancers. The Company's growing team ...

Aquasome

A platform nanoparticulate technology for biomolecular delivery in a broad range of industrial, personal use, and biomedical applications.

More Information about "BioMolecular Therapeutics" on BioPortfolio

We have published hundreds of BioMolecular Therapeutics news stories on BioPortfolio along with dozens of BioMolecular Therapeutics Clinical Trials and PubMed Articles about BioMolecular Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioMolecular Therapeutics Companies in our database. You can also find out about relevant BioMolecular Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...


Corporate Database Quicklinks



Searches Linking to this Company Record